(5S,8'R,9'S,13'S,14'S)-13'-ethyl-3'-methoxy-3-methylspiro[1,3-oxazolidine-5,17'-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-2-one | 69269-27-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (5S,8'R,9'S,13'S,14'S)-13'-ethyl-3'-methoxy-3-methylspiro[1,3-oxazolidine-5,17'-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-2-one
• CAS: 69269-27-8
• 化学式: C₂₃H₃₃NO₃
• 分子量: 371.52
• InChiKey: URKJFBVIAXNQKC-BQLVWXCYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.05
• 重原子数：
  27.0
• 可旋转键数：
  2.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  38.77
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (5S,8'R,9'S,13'S,14'S)-13'-ethyl-3'-methoxy-3-methylspiro[1,3-oxazolidine-5,17'-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-2-one 在 盐酸羟胺 作用下， 以 吡啶 为溶剂， 以48%的产率得到
  参考文献：
  名称：

  Synthesis of new spiro-steroids, II: Steroid-17-spiro-oxazolidinones*1

  摘要：

  New, potential aldosterone blocking 17-spiro-oxazolidinone derivatives with androstane, estrane and 13 beta-ethyl-gonane ring system were synthesized. 17S-Spiro-oxiranes were used as starting compounds and the oxazolidinone ring was built up in different ways. All compounds but one were devoid of considerable endocrine activities. 3-Oxo-13 beta-ethyl-gona-4,9(10),11-triene-17S-spiro-5'-(2'-oxo-3'-methyl)oxazolidine shows significant antiandrogen activity on s.c., but none on p.o. administration.

  DOI：

  10.1016/0039-128x(80)90138-5
• 作为产物：
  描述：

  N-ethoxycarbonyl-13β-ethyl-3-methoxy-17α-methylaminomethylgona-2,5(10)dien-17β-ol 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 以65%的产率得到(5S,8'R,9'S,13'S,14'S)-13'-ethyl-3'-methoxy-3-methylspiro[1,3-oxazolidine-5,17'-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-2-one
  参考文献：
  名称：

  Synthesis of new spiro-steroids, II: Steroid-17-spiro-oxazolidinones*1

  摘要：

  New, potential aldosterone blocking 17-spiro-oxazolidinone derivatives with androstane, estrane and 13 beta-ethyl-gonane ring system were synthesized. 17S-Spiro-oxiranes were used as starting compounds and the oxazolidinone ring was built up in different ways. All compounds but one were devoid of considerable endocrine activities. 3-Oxo-13 beta-ethyl-gona-4,9(10),11-triene-17S-spiro-5'-(2'-oxo-3'-methyl)oxazolidine shows significant antiandrogen activity on s.c., but none on p.o. administration.

  DOI：

  10.1016/0039-128x(80)90138-5